Intraventricularly Injected Olig2-NSCs Attenuate Established Relapsing–Remitting EAE in Mice

Cell Transplantation - United States
doi 10.3727/096368911x637443
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Therapeutic Administration of Mesenchymal Stem Cells Abrogates the Relapse Phase in Chronic Relapsing-Remitting EAE

Journal of Stem Cell Research & Therapy
2015English

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis

Neurotherapeutics
NeurologyPharmacology
2017English

Endocarditis Following Ocrelizumab in Relapsing-Remitting MS

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2020English

Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis

Neuropsychiatric Disease and Treatment
PsychiatryMental HealthBiological Psychiatry
2010English

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis

Archives of Neurology
2009English

Stressful Events Increase Exacerbations in Relapsing-Remitting Multiple Sclerosis

BMJ
2003English

Cerebrovascular Reactivity and Disease Activity in Relapsing-Remitting Multiple Sclerosis

Advances in Clinical and Experimental Medicine
BiochemistryMedicineGeneticsMolecular Biology
2020English

Natalizumab for Relapsing-Remitting Ms in the Uk Top Cohort

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2014English

Alemtuzumab: Evidence for Its Potential in Relapsing–remitting Multiple Sclerosis

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy